[1]
|
Bosman, F.T., Carneiro, F., Hruban, R.H., et al. (2010) WHO Classilication of Tumours of the Digestive System. 4th Edition, International Agency for Research on Cancer Press, Lyon, 196-250.
|
[2]
|
Elmugtaba, I.M., Kerolos, A., Zhai, Q.J., et al. (2017) Primary Hepatic Neuroendocrine Tumor with Unusual Thyroid Follicular-Like Morphologic Characteristics. Case Reports in Pathology, 2017, Article ID: 7931975.
https://doi.org/10.1155/2017/7931975
|
[3]
|
Quartey, B. (2011) Primary Hepatic Neuroendocrine Tumor: What Do We Know Now? World Journal of Oncology, 2, 209-216. https://doi.org/10.4021/wjon341w
|
[4]
|
杨秋霞, 吴静, 张嵘. 神经内分泌肿瘤的诊断研究进展[J]. 国际医学放射学杂志, 2011, 34(5): 418-421.
|
[5]
|
Trofimiuk-Müldner, M., Lewkowicz, E., Wysocka, K., et al. (2017) Epidemiology of Gastroenteropancreatic Neuroendocrine Neoplasms in Krakow and Krakow District in 2007-2011. Endokrynologia Polska, 68, 42-46.
https://doi.org/10.5603/EP.2017.0006
|
[6]
|
Dasari, A., Shen, C., Halperin, D., et al. (2017) Trends in the Incidence, Prevalence, and Survival Outcomes in Patients with Neuroendocrine Tumors in the United States. JAMA Oncology, 3, 1335-1342.
https://doi.org/10.1001/jamaoncol.2017.0589
|
[7]
|
De Luzio, M., Barbieri, A., Israel, G., et al. (2017) Two Cases of Primary Hepatic Neuroendocrine Tumors and a Review of the Current Literature. Annals of Hepatology, 16, 621-629. https://doi.org/10.5604/01.3001.0010.0313
|
[8]
|
Andreola, S., Lombardi, L., Audisio, R.A., et al. (1990) A Clinicopathologic Study of Primary Hepatic Carcinoid Tumors. Cancer, 65, 1211-1218.
https://doi.org/10.1002/1097-0142(19900301)65:5%3C1211::AID-CNCR2820650530%3E3.0.CO;2-M
|
[9]
|
Sioutos, N., Virta, S. and Kessimian, N. (1991) Primary Hepatic Carcinoid Tumor. Anelectron Microscopic and Immunohistochemical Study. American Journal of Clinical Pathology, 95, 172-175. https://doi.org/10.1093/ajcp/95.2.172
|
[10]
|
Gravante, G., De Liguori, C.Ni., Overton, J., et al. (2008) Primary Carcinoids of the Liver: A Review of Symptoms, Diagnosis and Treatments. Digestive Surgery, 25, 364-368. https://doi.org/10.1159/000167021
|
[11]
|
Gupta, S. (2013) Intra-Arterial Liver-Directed Therapies for Neuroendocrine Hepatic Metastases. Seminars in Interventional Radiology, 30, 28-38. https://doi.org/10.1055/s-0033-1333651
|
[12]
|
Yao, J.C., Hassan, M., Phan, A., et al. (2008) One Hundred Years after “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States. Journal of Clinical Oncology, 26, 3063-3072.
https://doi.org/10.1200/JCO.2007.15.4377
|
[13]
|
Modlin Irvin, M., Oberg, K., Chung, D.C., et al. (2008) Gastroenteropancreatic Neuroendocrine Tumours. Lancet Oncology, 9, 61-72. https://doi.org/10.1016/S1470-2045(07)70410-2
|
[14]
|
Beaumont, J.L., Cella, D., Phan, A.T., et al. (2012) Comparison of Health-Related Quality of Life in Patients with Neuroendocrine Tumors with Quality of Life in the General US Population. Pancreas, 41, 461-466.
https://doi.org/10.1097/MPA.0b013e3182328045
|
[15]
|
Shetty, P.K., Baliga, S.V., Balaiah, K., et al. (2010) Primary Hepatic Neuroendocrine Tumor: An Unusual Cystic Presentation. Indian Journal of Pathology and Microbiology, 53, 760-762. https://doi.org/10.4103/0377-4929.72078
|
[16]
|
Tohyama, T., Matsui, K. and Kitagawa, K. (2005) Primary Hepatic Carcinoid Tumor with Carcinoid Syndrome and Carcinoid Heart Disease: A Case Report of a Patient on Long-Term Follow-up. Internal Medicine, 44, 958-962.
https://doi.org/10.2169/internalmedicine.44.958
|
[17]
|
Chen, Q., Zhao, H., Zhao, J., Bi, X., Li, Z., Huang, Z., Zhang, Y., Zhou, J. and Cai, J. (2018) Clinical Features and Prognostic Factors of Cryptogenic Hepatocellular Carcinoma. Translational Cancer Research, 7, 729-737.
https://doi.org/10.21037/tcr.2018.06.06
|
[18]
|
Chen, Z., Xiao, H.-E., Ramchandra, P., et al. (2014) Imaging and Pathological Features of Primary Hepatic Neuroendocrine Carcinoma: An Analysis of Nine Cases and Review of the Literature. Oncology Letters, 7, 956-962.
https://doi.org/10.3892/ol.2014.1844
|
[19]
|
Hope, T.A., Bergsland, E.K., Bozkurt, M.F., et al. (2018) Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. Journal of Nuclear Medicine, 59, 66-74.
https://doi.org/10.2967/jnumed.117.202275
|
[20]
|
Ronot, M., Clift, A.K., Baum, R.P., et al. (2018) Morphological and Functional Imaging for Detecting and Assessing the Resectability of Neuroendocrine Liver Metastases. Neuroendocrinology, 106, 74-88.
https://doi.org/10.1159/000479293
|
[21]
|
Miki, M., Ito, T., Hijioka, M., et al. (2017) Utility of Chromogranin B Compared with Chromogranin A as a Biomarker in Japanese Patients with Pancreatic Neuroendocrine Tumors. Japanese Journal of Clinical Oncology, 47, 520-528.
https://doi.org/10.1093/jjco/hyx032
|
[22]
|
Arnold, R., Wilke, A., Rinke, A., et al. (2008) Plasma Chromogranin A as Marker for Survival in Patients with Metastatic Endocrine Gastroenteropancreatic Tumors. Clinical Gastroenterology and Hepatology, 6, 820-827.
https://doi.org/10.1016/j.cgh.2008.02.052
|
[23]
|
Jensen, E.H., Kvols, L., McLoughlin, J.M., et al. (2007) Biomarkers Predict Outcomes Following Cytoreductive Surgery for Hepatic Metastases from Functional Carcinoid Tumors. Annals of Surgical Oncology, 14, 780-785.
https://doi.org/10.1245/s10434-006-9148-z
|
[24]
|
Foster, J.H. and Berman, M.M. (1977) Solid Liver Tumors. Major Problems in Clinical Surgery, 22, 1-342.
|
[25]
|
Foster, J.H. and Lundy, J. (1981) Liver Metastases. Current Problems in Surgery, 18, 157-202.
https://doi.org/10.1016/S0011-3840(81)80009-3
|
[26]
|
Pavel, M., O’Toole, D., Costa, F., et al. (2016) ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology, 103, 172-185. https://doi.org/10.1159/000443167
|
[27]
|
Farley Heather, A. and Pommier Rodney, F. (2016) Treatment of Neuroendocrine Liver Metastases. Surgical Oncology Clinics of North America, 25, 217-225. https://doi.org/10.1016/j.soc.2015.08.010
|
[28]
|
Cannon, R., Ellis, S., Hayes, D., et al. (2013) Safety and Early Efficacy of Irreversible Electroporation for Hepatic Tumors in Proximity to Vital Structures. Journal of Surgical Oncology, 107, 544-549.
https://doi.org/10.1002/jso.23280
|
[29]
|
Mayo, S.C., de Jong, M.C., Bloomston, M., Pulitano, C., Clary, B.M., Reddy, S.K., et al. (2011) Surgery Versus Intra-Arterial Therapy for Neuroendocrine Liver Metastasis: A Multicenter International Analysis. Annals of Surgical Oncology, 18, 3657-3665. https://doi.org/10.1245/s10434-011-1832-y
|
[30]
|
Shen, C., Shih, Y.-C.T., Xu, Y., et al. (2015) Octreotide Long-Acting Repeatable among Elderly Patients with Neuroendocrine Tumors: A Survival Analysis of SEER-Medicare Data. Cancer Epidemiology, Biomarkers & Prevention, 24, 1656-1665. https://doi.org/10.1158/1055-9965.EPI-15-0336
|
[31]
|
Clift, A.K. and Frilling, A. (2014) Management of Patients with Hepatic Metastases from Neuroendocrine Tumors. Annals of Saudi Medicine, 34, 279-290. https://doi.org/10.5144/0256-4947.2014.279
|
[32]
|
Raymond, E., Dahan, L., Raoul, J.-L., et al. (2011) Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors. New England Journal of Medicine, 364, 501-513. https://doi.org/10.1056/NEJMoa1003825
|
[33]
|
Maroon, J., Kocha, W., Kvols, L., et al. (2006) Guidelines for the Diagnosis and Management of Carcinoid Tumours. Part 1: The Gaetrointestinal Tract. A Statement from a Canadian National Carcinoid Expert Group. Current Oncology, 13, 67-76. https://doi.org/10.3390/curroncol13020006
|
[34]
|
Öberg, K., Knigge, U., Kwekkeboom, D., et al. (2012) Neuroendocrine Gastro-Entero-Pancreatic Tumors: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 23, vii124-vii130.
https://doi.org/10.1093/annonc/mds295
|
[35]
|
Fazio, N., Granberg, D., Grossman, A., et al. (2013) Everolimus plus Octreotide Long-Acting Repeatable in Patients with Advanced Lung Neuroendocrine Tumors: Analysis of the Phase 3, Randomized, Placebo-Controlled RADIANT-2 study. Chest, 143, 955-962. https://doi.org/10.1378/chest.12-1108
|
[36]
|
Pavel, M.E., Becerra, C., Grosch, K., et al. (2017) Effect of Everolimus on the Pharmacokinetics of Octreotide long-Acting Repeatable in Patients with Advanced Neuroendocrine Tumors: An Analysis of the Randomized Phase III RADIANT-2 Trial. Clinical Pharmacology & Therapeutics, 101, 462-468. https://doi.org/10.1002/cpt.559
|
[37]
|
Ott Patrick, A., Bang, Y.-J., Piha-Paul, S.A., et al. (2019) T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated with Pembrolizumab Across 20 Cancers: KEYNOTE-028. Journal of Clinical Oncology, 37, 318-327.
https://doi.org/10.1200/JCO.2018.78.2276
|
[38]
|
Fan, Y., Ma, K., Wang, C., et al. (2016) Prognostic Value of PD-L1 and PD-1 Expression in Pulmonary Neuroendocrine Tumors. OncoTargets and Therapy, 9, 6075-6082. https://doi.org/10.2147/OTT.S115054
|